Effectiveness of Pfizer-BioNTech mRNA Vaccination Against COVID-19 Hospitalization Among Persons Aged 12–18 Years — United States, June–September 2021 | MMWR
COVID-19 Booster Shots are Now Available – What You Need to Know > TRICARE Newsroom > Articles
FDA approval of Pfizer's COVID-19 vaccine spurs American confidence: Harris Poll | Fierce Pharma
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months | NEJM
Healthcare Providers for 12 years of age and older, purple cap (must dilute) 12222022
Seroepidemiological study of factors affecting anti-spike IgG antibody titers after a two-dose mRNA COVID-19 vaccination in 3744 healthy Japanese volunteers | Scientific Reports
Is the Pfizer-BioNTech COVID vaccine still effective after 6 months?
Pfizer CEO confirms coronavirus vaccine trial may have results in October
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile | NEJM
County-level vaccination coverage and rates of COVID-19 cases and deaths in the United States: An ecological analysis - The Lancet Regional Health – Americas
The Moderna vaccine makes more antibodies than Pfizer's. Does it matter? | The Japan Times
Vaccines | Free Full-Text | Evaluating COVID-19 Booster Vaccination Strategies in a Partially Vaccinated Population: A Modeling Study
KFF COVID-19 Vaccine Monitor: September 2021 | KFF
What to know about booster shots if you received Johnson & Johnson's COVID-19 vaccine | PBS NewsHour
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study - The Lancet Infectious Diseases
Use of 15-Valent Pneumococcal Conjugate Vaccine Among U.S. Children: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022 | MMWR
Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50 | Nature Communications
